[go: up one dir, main page]

PT3810281T - Métodos para tratamento de cancro com anticorpos biespecíficos anti-cd3xmuc16 e anticorpos anti-pd-1 - Google Patents

Métodos para tratamento de cancro com anticorpos biespecíficos anti-cd3xmuc16 e anticorpos anti-pd-1

Info

Publication number
PT3810281T
PT3810281T PT197394729T PT19739472T PT3810281T PT 3810281 T PT3810281 T PT 3810281T PT 197394729 T PT197394729 T PT 197394729T PT 19739472 T PT19739472 T PT 19739472T PT 3810281 T PT3810281 T PT 3810281T
Authority
PT
Portugal
Prior art keywords
antibodies
cd3xmuc16
bisecticific
cancer
treatment
Prior art date
Application number
PT197394729T
Other languages
English (en)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of PT3810281T publication Critical patent/PT3810281T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT197394729T 2018-06-21 2019-06-20 Métodos para tratamento de cancro com anticorpos biespecíficos anti-cd3xmuc16 e anticorpos anti-pd-1 PT3810281T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862688251P 2018-06-21 2018-06-21

Publications (1)

Publication Number Publication Date
PT3810281T true PT3810281T (pt) 2024-08-02

Family

ID=67254001

Family Applications (1)

Application Number Title Priority Date Filing Date
PT197394729T PT3810281T (pt) 2018-06-21 2019-06-20 Métodos para tratamento de cancro com anticorpos biespecíficos anti-cd3xmuc16 e anticorpos anti-pd-1

Country Status (25)

Country Link
US (1) US11254752B2 (pt)
EP (2) EP4424712A3 (pt)
JP (1) JP7403480B2 (pt)
KR (1) KR20210023981A (pt)
CN (1) CN112312970A (pt)
AU (1) AU2019290170A1 (pt)
BR (1) BR112020025476A2 (pt)
CA (1) CA3103887A1 (pt)
CL (1) CL2020003256A1 (pt)
DK (1) DK3810281T3 (pt)
EA (1) EA202190088A1 (pt)
ES (1) ES2984972T3 (pt)
FI (1) FI3810281T3 (pt)
HU (1) HUE067985T2 (pt)
IL (1) IL279251A (pt)
MA (1) MA52962B1 (pt)
MX (1) MX2020013905A (pt)
PH (1) PH12020552115A1 (pt)
PL (1) PL3810281T3 (pt)
PT (1) PT3810281T (pt)
RS (1) RS65886B1 (pt)
SG (1) SG11202012137UA (pt)
TW (1) TW202005985A (pt)
WO (1) WO2019246356A1 (pt)
ZA (1) ZA202007599B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI682941B (zh) * 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US10556952B2 (en) 2015-03-30 2020-02-11 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to Fc gamma receptors
KR20210054528A (ko) 2018-08-31 2021-05-13 리제너론 파아마슈티컬스, 인크. Cd3/c20 이중특이적 항체에 대한 사이토카인 방출 증후군을 경감시키는 투약 전략
MX2023008949A (es) 2021-01-28 2023-10-23 Regeneron Pharma Composiciones y metodos para tratar el sindrome de liberacion de citocinas.
US20240174764A1 (en) * 2021-03-18 2024-05-30 Memorial Sloan-Kettering Cancer Center METHODS FOR TREATING GYNECOLOGIC CANCER USING COMBINATION THERAPY WITH ANTI-MUC16 x CD3 MULTISPECIFIC ANTIBODIES AND VEGF INHIBITORS
WO2023033022A1 (ja) 2021-08-31 2023-03-09 日本メジフィジックス株式会社 脱グリコシル化抗体の放射性複合体、及び、放射性医薬
KR20240103062A (ko) * 2021-11-24 2024-07-03 리제너론 파아마슈티컬스, 인크. 이중 특이적 항CD3 x MUC16 항체 및 항CTLA-4 항체로 암을 치료하는 방법
WO2023133280A1 (en) * 2022-01-07 2023-07-13 Regeneron Pharmaceuticals, Inc. Methods of treating recurrent ovarian cancer with bispecific anti-muc16 x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies
JP2025504795A (ja) 2022-01-10 2025-02-19 ナンチン リーズ バイオラブス カンパニー，リミティド 抗体及びその用途
CN119031932A (zh) * 2022-03-16 2024-11-26 第一三共株式会社 多特异性分子和免疫检查点抑制剂的组合
US20230357446A1 (en) 2022-04-11 2023-11-09 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
WO2024173830A2 (en) 2023-02-17 2024-08-22 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
BR0013581A (pt) 1999-08-23 2002-07-02 Dana Faber Cancer Inst Inc Pd-1, um receptor para b7-4, e usos para isto
AU2003288675B2 (en) 2002-12-23 2010-07-22 Medimmune Limited Antibodies against PD-1 and uses therefor
US8008449B2 (en) 2005-05-09 2011-08-30 Medarex, Inc. Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
ME02093B (me) 2007-06-18 2014-04-30 N V Organon Antitijela za humani receptor programirane smrti pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
US8114845B2 (en) 2008-08-25 2012-02-14 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
PL2975051T3 (pl) 2009-06-26 2021-09-20 Regeneron Pharmaceuticals, Inc. Wyizolowane z łatwością dwuswoiste przeciwciała o formacie natywnej immunoglobuliny
BR112013032552A2 (pt) 2011-07-24 2017-12-12 Curetech Ltd variantes de anticorpos monoclonais humanizados imunomoduladores
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
EA201890785A1 (ru) * 2015-09-23 2018-10-31 Ридженерон Фармасьютикалз, Инк. Оптимизированные биспецифические анти-cd3 антитела и их применение
MD3394103T2 (ro) 2015-12-22 2023-11-30 Regeneron Pharma Combinație de anticorpi anti-PD-1 și anticorpi bispecifici anti-CD20/anti-CD3 pentru tratamentul cancerului
TWI822521B (zh) 2016-05-13 2023-11-11 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
PT3515946T (pt) 2016-09-23 2022-08-04 Regeneron Pharma Anticorpos anti-muc16 (mucin 16)
PE20191034A1 (es) * 2016-10-14 2019-08-05 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15r y fragmentos de anticuerpo pd-1
WO2018099539A1 (en) 2016-11-29 2018-06-07 Horst Lindhofer Combination of t-cell redirecting multifunctional antibodies with immune checkpoint modulators and uses thereof

Also Published As

Publication number Publication date
PL3810281T3 (pl) 2024-11-04
EP3810281B1 (en) 2024-07-24
PH12020552115A1 (en) 2021-08-02
AU2019290170A1 (en) 2021-01-07
KR20210023981A (ko) 2021-03-04
IL279251A (en) 2021-01-31
MX2020013905A (es) 2021-03-09
EA202190088A1 (ru) 2021-03-22
ES2984972T3 (es) 2024-10-31
HUE067985T2 (hu) 2024-12-28
US20190389966A1 (en) 2019-12-26
FI3810281T3 (fi) 2024-08-14
EP4424712A3 (en) 2024-11-13
SG11202012137UA (en) 2021-01-28
US11254752B2 (en) 2022-02-22
CL2020003256A1 (es) 2021-04-30
BR112020025476A2 (pt) 2021-03-16
TW202005985A (zh) 2020-02-01
RS65886B1 (sr) 2024-09-30
MA52962A (fr) 2021-04-28
EP3810281A1 (en) 2021-04-28
EP4424712A2 (en) 2024-09-04
ZA202007599B (en) 2025-02-26
JP7403480B2 (ja) 2023-12-22
CN112312970A (zh) 2021-02-02
JP2021528423A (ja) 2021-10-21
CA3103887A1 (en) 2019-12-26
WO2019246356A1 (en) 2019-12-26
DK3810281T3 (da) 2024-08-19
MA52962B1 (fr) 2024-10-31

Similar Documents

Publication Publication Date Title
PT3810281T (pt) Métodos para tratamento de cancro com anticorpos biespecíficos anti-cd3xmuc16 e anticorpos anti-pd-1
ZA202004735B (en) Anti-pd-1 antibodies and methods of treatment
HK1255040A1 (zh) 治療癌症的抗pd-1抗體和雙特異性抗cd20/抗cd3抗體組合
IL267804A (en) Methods for treating cancer with anti-pd-1 antibodies
IL270814A (en) Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
IL262562A (en) Combination of anti-pd-1 antibodies and radiation to treat cancer
DK3458478T3 (da) Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
IL278772A (en) Antibodies against 40-OX and methods of use
CL2018000728A1 (es) Anticuerpos anti-cd19 humano humanizados y métodos de utilización
BR112019002331A2 (pt) anticorpos anti-siglec-7 para o tratamento do câncer e métodos para obtenção dos mesmos
HK1255916A1 (zh) 組織蛋白去乙醯酶抑制劑與免疫檢查點抑制抗體的合併癌症治療
IL266990A (en) Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens
IL273196A (en) Claudin 6 antibodies and methods of cancer treatment
RS63956B1 (sr) Humanizovana anti-c1s antitela i metode njihove upotrebe
PT3807316T (pt) Composições e métodos para tratamento de cancro
IL282478A (en) Materials and methods for treating cancer
HUE063119T2 (hu) Kezelési paradigma anti-CD19 antitest és venetoclax kombinációs kezeléshez
IL268460A (en) Treatment of bladder cancer with an antibody against pd-l1
IL287687A (en) Methods of treating cancer with an anti-pd-l1 antibody
IL282948A (en) Compositions and methods for treating cancer